



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Date: 24 February 2026**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: PRESS RELEASE**

Dear Sir/Madam,

Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a Press Release intended for public dissemination.

Thanking you.

Yours faithfully,

**Eris Lifesciences Limited**

---

**Milind Talegaonkar**  
**Company Secretary and Compliance Officer**  
**ICSI Mem No. A26493**

**Encl: a/a**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

## Eris Lifesciences Ltd Announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India

**Ahmedabad, India – 24<sup>th</sup> Feb 2026** — Eris Lifesciences Limited (“Eris Lifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a leading Indian branded formulations company, recently announced a strategic partnership with Natco Pharma Limited for the commercialisation of **Semaglutide** in India, reinforcing Eris’s commitment to expanding its leadership in the fast-growing diabetes and metabolic care segment.

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction. With India witnessing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment.

Eris has built a strong and scalable presence in diabetology over the years, supported by a wide specialist reach and deep engagement with endocrinologists, diabetologists and physicians across India. The addition of semaglutide is expected to further strengthen Eris’ portfolio in advanced diabetes therapies and enhance its participation in next-generation metabolic treatments.

This collaboration builds on both companies’ complementary strengths: Eris’s robust commercial and diabetes franchise presence, and Natco’s manufacturing and regulatory prowess in complex formulations.

### Strategic Partnership Details

**Regulatory Milestone:** Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market, paving the way for a launch expected in March 2026.

**Market Focus:** The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape.

### Leadership Commentary

**Mr. Amit Bakshi, Chairman & Managing Director, Eris Lifesciences Ltd**, said: “Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies, we believe Eris is well positioned to drive rapid adoption and enhance patient access in India.”

He further added that Eris has been proactively preparing its commercial strategy to participate meaningfully in the GLP-1 opportunity and views this partnership as a long-term value driver for the company.

### About Eris Lifesciences Ltd (BSE: 540596, NSE: ERIS):

Established in 2007, Eris is the youngest among the Top 20 pharma companies in India. With an annual branded formulations revenue of INR 3,000+ Cr as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including Oral Solids, Oral Liquids, Softgels, Ointments, Sprays & Gels, Sterile Injectables and Biologics in its 6 manufacturing facilities, and markets these products across India through a network of ~5,000 stockists and 5,00,000+ retail pharmacies.

Eris’ revenue and operating profit have grown 2.6x in the last 5 years, with FY25 revenue of INR 2,894 Cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 Cr over the last 3 years.

#### ERIS Lifesciences Ltd

## For Further Details, Please Contact:

### **Kruti Raval**

VP – Investor Relations and M&A  
[kruti@erislifesciences.com](mailto:kruti@erislifesciences.com)

### **Atul Modi**

Sr. Manager - Investor Relations  
[atul.modi@eritherapeutics.com](mailto:atul.modi@eritherapeutics.com)

## Safe Harbor:

This document includes forward-looking information and statements including statements concerning the outlook for our businesses. These statements are based on current expectations, estimates and projections that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, allocations of funds by the Governments in the healthcare sector, increasing competition and the conditions of our customers, suppliers and the pharmaceutical industry, global and Indian demand-supply conditions finished goods prices, cyclical demand and pricing in the company's principal markets, changes in government laws and regulations, tax regimes, our provisioning policies, economic and political developments within India and the countries within which the company conducts businesses and other factors such as litigation and labour negotiations.

Any forward-looking statement or information contained in this document speaks only as of the date of the statement. The company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, based on any subsequent development, information or events or otherwise unless it is required by Law.

## **ERIS Lifesciences Ltd**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, Gujarat 380054  
Email: [investor.relations@eris.co.in](mailto:investor.relations@eris.co.in); M: +91-79-30451111; CIN: L24232GJ2007PLC049867